Business Context and Reporting Period
Company: TherapeuticsMD, Inc. (TXMD)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Model: Pharmaceutical royalty company. Following the December 2022 "Mayne Transaction," the Company ceased commercial operations and now derives revenue from royalties on products (IMVEXXY, BIJUVA, ANNOVERA, and prenatal vitamins) licensed to Mayne Pharma (U.S.) and other partners (Knight, Theramex) internationally. Former commercial operations are reported as discontinued operations.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| License Revenue | $3,022 | $1,761 |
| Total Operating Expenses | $7,412 | $7,873 |
| Net Loss (Continuing Ops) | $(653) | $(2,312) |
| Net Loss (Total) | $(569) | $(2,181) |
| Cash and Cash Equivalents | $7,483 | $5,059 |
| Net Cash Provided by Operating Activities | $2,454 | $1,170 |
| Stockholders' Equity | $26,876 | $27,370 |
Debt: The Company has no outstanding debt. All obligations under the previous Financing Agreement were repaid in December 2022.
Material Changes vs. Prior Period
- Revenue Growth: License revenue increased 71.6% to $3.022 million, driven by higher sales of licensed products by Mayne Pharma and international partners.
- Expense Reduction: Total operating expenses decreased 5.9% to $7.412 million. This was primarily due to a significant reduction in patent impairment charges ($176k in 2025 vs. $1.268M in 2024), partially offset by higher bonus and investor relations costs.
- Improved Loss Position: Net loss from continuing operations narrowed by 71.8% to $653k, reflecting revenue growth and operational efficiencies.
- Cash Flow: Net cash provided by operating activities more than doubled to $2.454 million, driven by the reduced operating loss and favorable changes in working capital.
Guidance, Outlook, Risks, and Contingencies
Going Concern Warning
The Company's independent auditors have issued an opinion with an explanatory paragraph regarding substantial doubt about the Company's ability to continue as a going concern for the next twelve months. This is due to recurring losses, negative cash flows from discontinued operations, and reliance on royalty payments and potential future financing.
Legal Contingencies (Mayne Pharma)
The Company is engaged in significant litigation with Mayne Pharma ("Mayne Lawsuits") regarding net working capital allowances for payer rebates, wholesale distributor fees, and returns.
- Status: A magistrate judge recommended staying the lawsuit while parties submit net working capital claims to dispute resolution. Some claims were recommended for dismissal, while others were denied dismissal.
- Financial Impact: The Company has not accrued additional liability as the range of loss cannot be reasonably estimated. However, an adverse outcome could result in significant damages, offsets against future royalties, or indemnification obligations.
Intellectual Property Risks
Generic competitors (Teva, Sun Pharma) have filed Paragraph IV certifications challenging patents for IMVEXXY. Litigation is ongoing. A loss of patent exclusivity would reduce the royalty rate from 8.0%/7.5% to 2.0% on a product-by-product basis.
Liquidity Outlook
The Company has $7.5 million in cash. Future liquidity depends on royalty receipts, the resolution of the Mayne dispute, and the ability to raise additional capital. No drawdowns occurred under the Rubric Capital Subscription Agreement in 2025.
Investor Verification Checklist
- Going Concern Status: Verify the Company's specific plans to secure additional capital if royalty revenues decline or legal settlements are unfavorable.
- Mayne Lawsuit Resolution: Monitor the dispute resolution process regarding net working capital allowances, as this could materially impact future cash flows and balance sheet liabilities.
- Patent Litigation: Track the status of IMVEXXY patent challenges by Teva and Sun Pharma, as a loss could trigger a significant reduction in royalty rates.
- Royalty Receivables: Review the aging and collectability of the $17.2 million in royalty receivables (current and long-term), which are subject to potential offset by Mayne Pharma.
- Sublease Income: Confirm the stability of sublease income ($1.847M in 2025), which currently offsets a significant portion of operating lease expenses.